August 2014 in “Acta Crystallographica” This study found that the dissolution profiles of different finasteride polymorphs may affect the quality of finasteride capsules, highlighting the need for polymorphic quality control.
November 2005 in “Journal of Investigative Dermatology Symposium Proceedings”
September 2020 in “Oxford University Press eBooks” This article discusses how understanding a genetic condition with a 5-alpha reductase mutation led to developing finasteride to treat benign prostatic hyperplasia and male pattern baldness, reporting no new research results.
13 citations
,
February 2015 in “Journal of Pharmaceutical Sciences” This study found that the polymorphic forms I, II, and III of finasteride can be prepared purely, with form III being identical to what was previously referred to as form X.
April 2006 in “The Journal of Urology” This study investigates the potential influence of genetic variations in the 5α-reductase type 2 gene on the effectiveness of finasteride treatment for benign prostatic hyperplasia, but it reports no new clinical results.
61 citations
,
April 2007 in “Journal of Pharmaceutical Sciences” This study reported new crystallographic structures and polymorphs of finasteride, including several solvates with distinct X-ray diffraction patterns and thermally characterized properties.